Hebei Senlang Biotechnology Inc., Ltd. Deal History & Licensing Activity
Hebei Senlang Biotechnology Inc., Ltd. is a biotech. Over the past three years, Hebei Senlang Biotechnology Inc., Ltd. has been involved in 2 licensing and acquisition transactions, with a primary focus on CAR-T (4 deals). The company currently has 9 active clinical trials, primarily in Hematological Malignancies.
Deals (12mo)
2
Active Trials
9
Top Modality
CAR-T
Focus Area
Hematological Malignancies
Hebei Senlang Biotechnology Inc., Ltd. Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Hebei Senlang Biotechnology Inc., Ltd. in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| In vivo CAR-T platform | Tempest Therapeutics | CAR-T | Preclinical | option | Sep 14, 2026 |
| TPST-4003 | Hebei Senlang Biotechnology | CAR-T | Preclinical | collaboration | Jul 21, 2026 |
Hebei Senlang Biotechnology Inc., Ltd. Pipeline Focus
Therapeutic areas and modalities where Hebei Senlang Biotechnology Inc., Ltd. is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Hebei Senlang Biotechnology Inc., Ltd. Clinical Pipeline
Hebei Senlang Biotechnology Inc., Ltd. has 9 active clinical trials across 5 development phases.
1
Early Phase 1
2
Not Applicable
2
Phase 1
2
Phase 1/2
2
Phase 2
See How Your Asset Matches Hebei Senlang Biotechnology Inc., Ltd.'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Hematological Malignancies assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
CAR-T Benchmarks
Upfront, milestone, and royalty benchmarks for car-t deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Hebei Senlang Biotechnology Inc., Ltd. Licensing & Deal Activity
Hebei Senlang Biotechnology Inc., Ltd. is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Hebei Senlang Biotechnology Inc., Ltd. ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Hebei Senlang Biotechnology Inc., Ltd. include Hematological Malignancies (6 deals and trials), Other (2 deals and trials), Immunology (2 deals and trials), and Autoimmune (1 deal and trial). In terms of modality, Hebei Senlang Biotechnology Inc., Ltd. has shown particular interest in car-t.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Hebei Senlang Biotechnology Inc., Ltd. and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Hebei Senlang Biotechnology Inc., Ltd.'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.